IMBRUVICA® for WMIMBRUVICA® for WM

IMBRUVICA®
(ibrutinib)
for WM

HomeWMIMBRUVICA® for WM

IMBRUVICA® Can Be Used Alone or in Combination With Rituximab1

In a clinical trial of 150 untreated and previously treated patients with WM who received IMBRUVICA® with rituximab:

75%

lower risk of disease progression

Adults with WM who took IMBRUVICA® + rituximab were 75% less likely to have their disease worsen or die compared to those taking rituximab alone. At an overall follow-up of 63 months, 29% of patients treated with IMBRUVICA® in combination with rituximab therapy experienced disease progression or death compared to 67% of patients treated with rituximab monotherapy. Adding IMBRUVICA® to rituximab more than doubled response rates compared to rituximab alone (76% response rate for IMBRUVICA® + rituximab vs 31% for rituximab).

IMBRUVICA® is the first FDA-approved therapy for WM

In a clinical trial of 63 previously treated WM patients who received IMBRUVICA® alone:

62%

response rate

62% (39 patients) had a response to IMBRUVICA®, which means that their doctor observed fewer signs of the disease as seen through blood tests, X‑rays, CT scans, and/or bone marrow tests.1,2 The median amount of time to respond to IMBRUVICA® treatment was 1.2 months.

IMBRUVICA® will not work for every patient. Individual results may vary.

IMBRUVICA® By Your Side Patient Support Program

Starting IMBRUVICA®?

Get information and resources to support you along your treatment journey.*

Explore Support Options


What you should know about the side effects of IMBRUVICA®

IMBRUVICA® may cause serious side effects, including1:

  • Bleeding problems (hemorrhage)

  • Infections

  • Heart rhythm problems (ventricular arrhythmias, atrial fibrillation, and atrial flutter), heart failure and death

  • High blood pressure (hypertension)

  • Decrease in blood cell counts

  • Second primary cancers

  • Liver problems

  • Tumor lysis syndrome (TLS)†

†TLS is a disorder caused by the fast breakdown of cancer cells, which can lead to kidney failure and other abnormalities.

The most common side effects in the WM clinical study during which IMBRUVICA® was administered in combination with rituximab were1:

  • Bruising

  • Muscle, bone, and joint pain

  • Bleeding

  • Diarrhea

  • Rash

  • Nausea

  • Hypertension

In the WM clinical study for IMBRUVICA® administered in combination with rituximab, 5% of patients stopped taking IMBRUVICA® therapy because of side effects.3

The most common side effects during ibrutinib single agent therapy study in previously treated WM patients were1:

  • Low white blood cell count

  • Low blood platelet count

  • Diarrhea

  • Bruising

  • Bleeding

  • Low red blood cell count

  • Nausea

  • Rash

  • Muscle, bone, and joint pain

In the WM clinical trials with ibrutinib single agent therapy, 6% of patients stopped taking IMBRUVICA® due to side effects and 11% of patients had their dosage reduced due to side effects.4

This is not a complete list of side effects. Others may occur. Tell your doctor if you think you are experiencing side effects.

Many WM resources, one location
Many WM resources, one location

Watch a video featuring a patient living with WM. Plus, access educational information, support communities, and more.

Get Started

IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have. By Your Side Registered Nurses are provided by Johnson & Johnson and its affiliates and Pharmacyclics LLC, an AbbVie Company, and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

References: 1. IMBRUVICA® (ibrutinib) Prescribing Information. 2. Leukemia & Lymphoma Society. Waldenström macroglobulinemia. Accessed August 6, 2025. https://www.lls.org/sites/default/files/2021-07/FS20_Waldenstrom_FactSheet_2021.pdf 3. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378(25):2399-2410. 4. Data on file. Pharmacyclics LLC.